SPX-101 is a Novel ENaC-targeted Therapeutic for Cystic Fibrosis that Restores Mucus Transport.
about
Cytokine-Ion Channel Interactions in Pulmonary Inflammation.Nonclinical safety assessment of SPX-101, a novel peptide promoter of epithelial sodium channel internalization for the treatment of cystic fibrosis.The COPD Pipeline XXXVI.SPX-101 Is a Promising and Novel Nebulized ENaC Inhibitor.Mucociliary Clearance in Mice Measured by Tracking Trans-tracheal Fluorescence of Nasally Aerosolized BeadsRecent advances in developing therapeutics for cystic fibrosis
P2860
SPX-101 is a Novel ENaC-targeted Therapeutic for Cystic Fibrosis that Restores Mucus Transport.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
SPX-101 is a Novel ENaC-target ...... that Restores Mucus Transport.
@en
type
label
SPX-101 is a Novel ENaC-target ...... that Restores Mucus Transport.
@en
prefLabel
SPX-101 is a Novel ENaC-target ...... that Restores Mucus Transport.
@en
P2093
P2860
P1476
SPX-101 is a Novel ENaC-target ...... that Restores Mucus Transport.
@en
P2093
Dale J Christensen
David W Scott
Juan R Sabater
Juliana Sesma
Matthew P Walker
Robert Tarran
Timothy J Stuhlmiller
Timothy M Crowder
William M Abraham
P2860
P356
10.1164/RCCM.201612-2445OC
P407
P577
2017-05-08T00:00:00Z